• Corpus ID: 22253521

Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.

@article{Maillard2000TasosartanEA,
  title={Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.},
  author={Marc Maillard and Julien Rossat and Hans Rudolf Brunner and Michel Burnier},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2000},
  volume={295 2},
  pages={
          649-54
        }
}
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. In this study we evaluated the relative contribution of tasosartan and enoltasosartan to the overall pharmacological effect of tasosartan. AngII receptor blockade effect of single doses of tasosartan (100 mg p.o. and 50 mg i.v) and enoltasosartan (2.5 mg i.v.) were compared in 12 healthy subjects in a randomized, double blind, three-period… 
In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor Antagonist
TLDR
When administered intravenously in rats, telmisartan is 10-fold more potent than irbesartan and comparable to candesartan, and ex vivo assessment of the AT1 receptor blockade using an in vitro AngII receptor binding assay shows similar results.
Pharmacological Differences among Angiotensin II Receptor Antagonists
  • G. Belz
  • Medicine
    Blood pressure. Supplement
  • 2001
TLDR
Comparative trials have indicated that both irbesartan and candesartan show greater clinical efficacy in lowering blood pressure than losartan, and aldosterone levels following Ang II stimulation were blunted to a greater extent, following administration of irbsartan.
Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues.
TLDR
There is still a need for novel analogues with better pharmacological and financial profiles for AT(1) antagonists, and in vivo studies showed that MMK molecules, which fall in the same class of MM1, had a significant antihypertensive activity, however, in vitro affinity Studies showed that losartan has considerably higher affinity.
Angiotensin II receptor antagonist treatment during pregnancy.
TLDR
It is concluded that pharmacological suppression of the fetal renin-angiotensin system through ACE inhibition or AT1 receptor blockade seems to disrupt fetal vascular perfusion and renal function.
The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D, L-sotalol.
TLDR
Plasma protein binding does reduce APD prolongation seen with bound drugs, but this effect is not well correlated with the calculated plasma protein binding or expected clinical free fraction, and thus caution should be exercised when assigning a predictive safety window.
Does protein binding modulate the effect of angiotensin II receptor antagonists?
TLDR
In vitro AT 1-antagonistic effects of different Ang II receptor antagonists were differentially affected by the presence of human plasma, with rightward shifts of the IC50 ranging from one to several orders of magnitude.
Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation.
TLDR
It is found that oxazolone and imidazol one derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor and this molecule is investigated in further tests.
Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
TLDR
It is found that oxazol one and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor.
Design, synthesis, and antihypertensive evaluation of 2′-tetrazolyl and 2′-carboxy-biphenylylmethyl-pyrrolidine scaffolds substituted at their N1, C3, and C4 positions as potential angiotensin II AT1 receptor antagonists
A series of novel 2′-tetrazolyl- and 2′-carboxy-biphenylylmethyl-pyrrolidine derivatives (VIIIa–d, IX, X, XIa–d, XII, XIII, XIVa–d, XV ,and XVI) were designed and evaluated as Ang II AT1 receptor
Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing
TLDR
It is reported previously that 80 mg valsartan and 50 mg losartan provide less receptor blockade than 150 mg irbesartan in normotensive subjects and the importance of drug dosing in mediating these differences is investigated.
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
TLDR
It is demonstrated that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects.
Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.
TLDR
UR-7247 is a long-lasting, well-tolerated AT1 receptor in healthy subjects and has a very long plasma elimination half-life, which may be due to a high but also tight binding to protein binding sites.
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study
TLDR
These results demonstrate that tasosartan at 50 to 200 mg given once a day over a titration period of 10 weeks was effective and safe in the treatment of essential hypertension.
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
  • H. Brunner
  • Medicine
    American journal of hypertension
  • 1997
TLDR
The pharmacokinetics and pharmacodynamics of irbesartan are not altered in renally or hepatically impaired patients, probably owing to excretion characteristic by both biliary and renal routes, or by differences in gender or age.
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
TLDR
The pharmacokinetic/pharmacodynamic analysis performed with the three antagonists suggest that the AT-1 receptor-binding assay works as a bioassay that integrates the antagonistic property of all active drug components of the plasma.
Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension
TLDR
Tolerability data for 1420 patients with essential hypertension who were enrolled in eight double-masked, controlled clinical trials and who received tasosartan, a long-acting, nonpeptidic angiotensin II AT 1 receptor blocker are summarized.
DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan
TLDR
The results indicate that multiple factors determine the in vivo potency of angiotensin II antagonists, including affinity for and distribution to the receptor as modulated by plasma binding.
Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.
TLDR
A molecular modeling study provides a rationale for the role of the enol group of 8 in AT1 receptor binding and contributes to the excellent profile of the compound.
Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists
TLDR
The characterisation of the pharmacokinetic-pharmacodynamic relationships of nonpeptide angiotensin antagonists in humans deserves further refinement for designing optimal therapeutic regimens and proposing dosage adaptations in specific conditions.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension
TLDR
In conclusion, tasosartan at dosages of 10, 30, 100, or 300 mg given once daily produced a significant and dose-related reduction in both clinic and ambulatory BP that was maintained over the 24-h period.
...
1
2
...